Atypical Hemolytic Uremic Syndrome (aHUS)

What is Atypical hemolytic uremic syndrome?

Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening genetic disorder that affects the body’s complement system, leading to uncontrolled blood clotting in small blood vessels throughout the body. This condition causes the destruction of red blood cells, a dangerous drop in platelet count, and acute kidney injury. aHUS primarily affects children and young adults, though it can occur at any age, with an estimated incidence of approximately 0.5 cases per million people per year. Unlike typical hemolytic uremic syndrome, which is usually triggered by bacterial infections, aHUS is caused by genetic mutations that disrupt the body’s ability to regulate the complement cascade, a critical part of the immune system.

Key statistics

Symptoms

Primary symptoms: Fatigue, pale skin, easy bruising, decreased urination, swelling, confusion, seizures, high blood pressure.

The clinical presentation of aHUS typically develops rapidly over days to weeks. Early symptoms often include extreme fatigue and weakness due to severe anemia from red blood cell destruction. Patients frequently experience pale skin and mucous membranes, along with easy bruising and bleeding due to low platelet counts.

Kidney involvement manifests as decreased urine output, swelling in the legs and face, and high blood pressure. Neurological symptoms can be particularly concerning and may include confusion, irritability, seizures, stroke-like episodes, and changes in vision. Some patients experience abdominal pain, nausea, and vomiting.

Submit Your Paper

The condition can affect multiple organ systems beyond the kidneys, including the brain, heart, lungs, and gastrointestinal tract. Respiratory symptoms may include shortness of breath and chest pain. In severe cases, patients may develop heart rhythm abnormalities or heart failure due to the widespread blood vessel damage.

Causes and risk factors

aHUS is caused by dysregulation of the complement system, a network of proteins that helps the immune system fight infections and clear damaged cells. Genetic mutations affecting complement regulation are found in 50-70% of patients with aHUS. The most commonly affected genes include CFH, CFI, MCP (CD46), C3, CFB, and THBD.

These mutations lead to excessive complement activation on cell surfaces, particularly affecting the kidneys and other organs. The condition follows various inheritance patterns depending on the specific gene involved – some are autosomal dominant (requiring only one mutated copy), while others are autosomal recessive (requiring two mutated copies) or X-linked.

Environmental triggers can precipitate aHUS episodes in genetically susceptible individuals. These triggers include infections (particularly respiratory or gastrointestinal), pregnancy, certain medications, surgery, or other significant physical stressors. Some cases appear to be acquired, involving autoantibodies against complement regulatory proteins rather than genetic mutations.

Prevention

Primary prevention of aHUS is not possible since it is a genetic disorder. However, genetic counseling and testing are valuable for families with a history of aHUS, as this can identify at-risk individuals and inform reproductive decisions.

Carrier testing is available for family members of affected individuals, though the clinical significance varies by gene and inheritance pattern. Preimplantation genetic diagnosis may be considered for families with known pathogenic mutations.

Secondary prevention focuses on avoiding known triggers in diagnosed patients. This includes prompt treatment of infections, careful management during pregnancy, and avoiding certain medications known to trigger complement activation. Patients should receive appropriate vaccinations against encapsulated bacteria, especially if receiving complement-inhibiting therapy.

Complications

Without treatment, aHUS can lead to severe, life-threatening complications. Kidney failure is the most common serious complication, with up to 50% of patients progressing to end-stage renal disease requiring dialysis or kidney transplantation.

Neurological complications can include permanent brain damage, stroke, seizure disorders, and cognitive impairment. Cardiovascular complications may involve heart failure, rhythm disturbances, and increased risk of heart attack due to the widespread vascular damage.

Long-term complications can affect quality of life significantly, including chronic kidney disease with associated bone disease and anemia, hypertension requiring multiple medications, and increased risk of infections. Some patients experience recurrent episodes of aHUS, particularly during times of stress or illness.

The psychological impact of living with a rare, chronic disease can lead to anxiety, depression, and social isolation, particularly affecting children’s development and educational progress.

Diagnosis

Diagnosing aHUS requires a combination of clinical presentation and laboratory findings, as there is no single definitive test. The diagnosis is based on the presence of the classic triad: microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and acute kidney injury.

Laboratory tests reveal hemoglobin levels typically below 10 g/dL with evidence of hemolysis including elevated lactate dehydrogenase, decreased haptoglobin, and the presence of schistocytes (fragmented red blood cells) on blood smear examination. Platelet counts are usually below 150,000 per microliter.

Kidney function tests show elevated creatinine and blood urea nitrogen, with urinalysis revealing proteinuria and hematuria. ADAMTS13 activity levels are checked to rule out thrombotic thrombocytopenic purpura, a similar condition.

Genetic testing is performed to identify mutations in complement regulatory genes, though results may take several weeks. Complement studies including C3, C4, and factor H levels can provide additional diagnostic information.

Kidney biopsy, when feasible, may show characteristic findings of thrombotic microangiopathy affecting the glomeruli and small vessels.

Treatment

The cornerstone of aHUS treatment involves complement inhibition using monoclonal antibodies. Eculizumab was the first approved treatment, administered intravenously every two weeks after an initial loading period. Ravulizumab, a newer longer-acting complement inhibitor, can be given every eight weeks and offers improved convenience.

These medications work by blocking C5, a key component of the complement cascade, preventing the formation of the membrane attack complex that damages cells. Treatment typically begins as soon as the diagnosis is suspected and continues indefinitely for most patients.

Supportive care is crucial and may include plasma exchange or plasmapheresis in acute cases before specific therapy is available. Blood transfusions may be necessary for severe anemia, though they should be used judiciously. Dialysis may be required for acute kidney failure.

Antihypertensive medications, particularly ACE inhibitors or angiotensin receptor blockers, help manage high blood pressure and provide kidney protection. Iron and folate supplementation may be needed to address deficiencies from chronic hemolysis.

Prognosis

The prognosis for aHUS has improved dramatically with the introduction of complement-inhibiting therapies. Before these treatments were available, mortality rates reached 25%, with many survivors requiring permanent dialysis or kidney transplantation.

With prompt diagnosis and appropriate treatment using complement inhibitors, most patients experience rapid improvement in blood counts and stabilization of kidney function. However, the extent of kidney recovery depends on how quickly treatment is initiated and the degree of damage present at diagnosis.

Long-term studies show that patients treated with complement inhibitors can maintain stable kidney function and normal blood counts. Some patients may be able to discontinue treatment after several years, though this requires careful monitoring and should only be done under expert supervision.

The overall life expectancy for patients with well-managed aHUS can approach normal, though long-term cardiovascular and kidney health require ongoing monitoring and management.

Quality of life

Living with aHUS requires significant lifestyle adjustments, particularly around medical management and monitoring. Regular infusions every 2-8 weeks can impact work and school schedules, though many patients adapt well to this routine.

Diet modifications may be necessary if kidney function is impaired, including restrictions on sodium, phosphorus, and potassium. Adequate protein intake is important, especially during recovery phases. Staying well-hydrated is crucial, though fluid restrictions may be necessary in some cases.

Exercise is generally encouraged as tolerated, though patients should avoid extreme physical stress that might trigger disease flares. Regular moderate activity can help maintain cardiovascular health and bone strength.

Mental health support is important, as living with a rare disease can be isolating. Connecting with other patients through support groups and online communities can provide valuable emotional support and practical advice. Professional counseling may be beneficial for patients and families adjusting to the diagnosis.

Educational accommodations may be needed for children, including flexible scheduling for medical appointments and modified activities during illness episodes.

Pregnancy and fertility

Pregnancy represents a particular risk for women with aHUS, as it can trigger disease flares or first episodes in genetically susceptible individuals. Pre-conception counseling is essential to optimize health before pregnancy and plan appropriate monitoring and treatment.

Eculizumab and ravulizumab can be safely used during pregnancy and are often continued throughout pregnancy and the postpartum period in women with aHUS. Close collaboration between hematologists, nephrologists, and maternal-fetal medicine specialists is crucial.

Fertility is generally not directly affected by aHUS, though kidney damage may impact overall health and pregnancy outcomes. Genetic counseling should be offered to discuss inheritance patterns and reproductive options, including preimplantation genetic diagnosis for families with identified mutations.

Children

Pediatric aHUS often presents more acutely than adult-onset disease and may be initially mistaken for typical HUS following diarrheal illness. Children may have more severe neurological symptoms, including seizures and altered mental status.

Growth and development can be affected by chronic kidney disease and anemia. Nutritional support and growth hormone therapy may be necessary in some cases. Educational support services should be engaged early to address any learning difficulties related to neurological complications.

Vaccination schedules may need modification, particularly in children receiving complement inhibitor therapy, who have increased susceptibility to infections with encapsulated bacteria like meningococcus.

Transition to adult care requires careful planning, typically beginning in mid-adolescence, to ensure continuity of the complex medical management required for aHUS.

When to see a doctor

Immediate medical attention is required for symptoms suggesting aHUS, including unexplained fatigue with pale skin, easy bruising or bleeding, decreased urination, swelling in the face or legs, confusion, seizures, or severe headaches.

Patients with diagnosed aHUS should seek urgent care for signs of disease flare, including new neurological symptoms, significant changes in urine output, worsening swelling, or severe fatigue. Fever or signs of infection require prompt evaluation due to increased infection risk from complement inhibitor therapy.

Regular monitoring with hematology and nephrology specialists is essential for ongoing management, typically every 3-6 months when stable. More frequent visits may be needed during treatment adjustments or periods of instability.

Regional context

Limited data exists regarding aHUS prevalence specifically in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries. The genetic founder effects observed in some populations may influence the specific mutation profiles seen in these regions.

Healthcare infrastructure and access to specialized treatments like complement inhibitors may vary significantly across the region. International collaboration and telemedicine consultations can help ensure appropriate diagnosis and management in areas with limited local expertise.

We invite healthcare professionals and researchers from the region to contribute their experiences and data to improve our understanding of aHUS in these populations through the Global Medical Journal.

Research and clinical trials

Current research focuses on developing new complement inhibitors with improved convenience and efficacy, understanding which patients may safely discontinue treatment, and investigating combination therapies for resistant cases.

Novel therapeutic approaches being studied include longer-acting complement inhibitors, oral complement inhibitors, and treatments targeting different points in the complement cascade. Gene therapy approaches are being explored for patients with specific genetic mutations.

Clinical trials are investigating biomarkers to predict disease flares and guide treatment decisions. ClinicalTrials.gov maintains current listings of active studies for patients interested in participating in research.

Recent breakthroughs include the development of subcutaneous complement inhibitors and improved understanding of genetic modifiers that influence disease severity and treatment response.

Frequently asked questions

Is aHUS contagious?

No, aHUS is not contagious. It is a genetic disorder affecting the complement system and cannot be transmitted from person to person, unlike typical HUS which can be caused by bacterial infections.

Will I need treatment for life?

Most patients require long-term treatment with complement inhibitors, though some may be able to discontinue therapy after several years of stability. The decision to stop treatment should only be made with expert medical supervision and careful monitoring.

Can I have children if I have aHUS?

Yes, many people with aHUS can have children, though pregnancy requires specialized medical management and carries some additional risks. Genetic counseling is recommended to discuss inheritance patterns and reproductive options.

How quickly does treatment work?

Most patients begin to see improvement in blood counts within days to weeks of starting complement inhibitor therapy. Kidney function may take longer to recover and may not return to completely normal levels depending on the extent of initial damage.

What should I do if I think I have aHUS?

Seek immediate medical attention, preferably at a hospital with hematology and nephrology specialists. Early diagnosis and treatment are crucial for the best outcomes. Don’t wait to see if symptoms improve on their own.

Support and resources

• aHUS Alliance: ahusalliance.org – Global patient advocacy organization
• National Organization for Rare Disorders (NORD): rarediseases.org
• Orphanet: orpha.net – European reference portal for rare diseases
• EURORDIS: eurordis.org – European rare disease advocacy
• Global Genes: globalgenes.org – Rare disease patient advocacy

Related conditions

• Thrombotic thrombocytopenic purpura
• Typical hemolytic uremic syndrome
• Complement deficiency disorders
• Microangiopathic hemolytic anemia
• Chronic kidney disease

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.